Alias: CJC-1295 Acetate;
CAS No.: 863288-34-0
Molecular Formula: C165H271N47O46
Molecular Weight: 3649.30
Purity (HPLC): 98.0%
CJC-1295 DAC and CJC-1295 (also known as Modified GRF 1-29) are both Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life that can last up to approximately 8 days. Many a scientist have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered to be much more natural as they produce a short pulse.
Usage: An obstetric drug used to control postpartum hemorrhaging.
CJC-1295 is an injectable peptide used to increase GH production. This peptide is a hormone releasing hormone (GHRH) mimetic, or analog. That is to say, it works in the same way as GHRH, and may be referred to as being a GHRH.
The principal use of CJC-1295 is to provide increased GH levels, which also results in increased IGF-1 levels. An increase in these levels can aid fat loss and in some instances can aid muscle gain as well. Generally, a product in the GHRH category, including CJC-1295, is chosen as an alternate to using GH, and only rarely is combined with GH.